More evidence recently published by the 2011 Pharmaceutical R&D Factbook indicates that the pharma industry’s productivity is continuing to decline. Fewer new molecular entities were launched in 2010 than in any other year in the past decade. The number of drugs entering Phase I, II and III clinical trials is also declining. R&D expenditure has also dropped to a three year low of $68 billion.
I am a freelance science writer specialising in physics, astronomy, science funding and research policy. I write for a variety of online and print journals. In my day job, I work as a Research Facilitator in the Department of Physics at the University of Oxford.
Pharma grinding to a hault? – Euroscientist
July 11th, 2011
LAB RANT: Big Pharma – Laboratory News
March 1st, 2011
Last month, the world’s largest drugmaker, Pfizer, announced the closure of their 140-hectar site in Sandwich, Kent making 2,400 workers redundant. Pfizer are the latest in a stream of pharmaceutical giants who are “realigning their global R&D footprints”. What does this mean for UK R&D and the future of biomedical research? Leila Sattary investigates the major drug companies who are externalising their innovation.
Read full article – Subscribe to Laboratory News
Total visits: